UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data shown on the profile page to:

http://www.ucl.ac.uk/finance/secure/research/post_award
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
 More search options
Prof John Collinge
National Hospital for Neurology & Neurosurgery, UCL
Queen Square
London
WC1N 3BG
Appointment
  • Professor of Neurology
  • Neurodegenerative Diseases
  • Institute of Neurology
  • Faculty of Brain Sciences
 
 
Biography

John Collinge is Professor of Neurology and Head of the Department of Neurodegenerative Disease at the UCL Institute of Neurology, and Director of the MRC Prion Unit. He also directs the NHS National Prion Clinic at the adjacent National Hospital for Neurology and Neurosurgery. Professor Collinge trained in medicine at the University of Bristol and in neurology at St Mary’s Hospital and the National Hospital for Neurology and Neurosurgery in London. He is committed to highly multidisciplinary research and the seamless integration of basic laboratory and clinical research. He established the MRC Prion Unit at Imperial College in 1998 where he held the positions of Wellcome Senior Clinical Fellow and then Wellcome Principal Clinical Fellow. His laboratory demonstrated in 1996 that the new human prion disease, variant CJD, was caused by the same prion strain as that causing BSE in cattle and has been responsible for a number of key advances in the field. Professor Collinge has served on numerous Government advisory committees on prion disease at a national, European Union and international level. He is committed to public communication of the Unit’s research and gives many media interviews. He is a Founder Fellow of the Academy of Medical Sciences, a Fellow of the Royal Society and was awarded a CBE for services to medical research.

Research Groups
Research Themes
Research Summary

The Department of Neurodegenerative Disease’s research portfolio encompasses prion diseases (predominantly within the embedded MRC Prion Unit), Alzheimer’s disease and related disorders, Huntington’s disease, motor neurone disease and frontotemporal dementia and studies of the pathways of cellular senescence. The research philosophy is to combine basic and clinical translational research; many of the key contributions towards understanding the basic biology of these diseases have come from clinical and neuropathological observations, and efficient translation of basic laboratory research to the clinic is essential to provide benefits for patients at the earliest opportunity.

The MRC Prion Unit was established in 1998 and is located at the UCL Institute of Neurology where it is closely integrated with the University Department of Neurodegenerative Disease. The Unit was formed to provide a national centre of excellence with all necessary facilities to pursue a major long-term research strategy in prion and related diseases. 

Prions, unlike other infectious agents or germs, appear to lack their own genes and consist of aggregated misshapen forms of one of the body’s own proteins, the prion protein or PrP. Despite lacking genes, prions can exist as distinct strains with quite different properties. These unique features have wide implications in biology and evolution, and prions and prion diseases are of intense international research interest. However, in addition to the importance of this basic science, the Unit’s mission is also to tackle key public health issues posed by bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD).

It is becoming increasingly clear that other much commoner degenerative brain diseases, such as Alzheimer’s and Parkinson’s disease, also involve accumulation of rogue or abnormal forms of one or more of the body’s proteins resulting in damage to brain cells. Prion diseases, in addition to their intrinsic interest and importance, can be considered a paradigm for these other “protein misfolding” diseases. 

Our research programmes are highly multidisciplinary and focus both on areas of public health concern and a long-term approach to the understanding of prion disease. They include studies of molecular structure, genetics, biochemistry, immunology, cell and animal models, and clinical research - including treatment trials. Two major programmes to develop novel therapies are underway.

Academic Background
1998 FRCP Fellow of the Royal College of Physicians Royal College of Physicians
1992 MD Doctor of Medicine University of Bristol
1984 MB.ChB Bachelor of Medicine, Bachelor of Surgery University of Bristol
1981 BSc Hons Bachelor of Science (Honours) University of Bristol
  MRCP Member of the Royal College of Physicians Royal College of Physicians
Please report any queries concerning the data shown on this page to:

https://www.ucl.ac.uk/hr/helpdesk/helpdesk_web_form.php
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by